The Efficacy of Ferumoxytol for Iron Deficiency Anemia : A Meta-Analysis of Randomized Controlled Trials
© 2019 S. Karger AG, Basel..
INTRODUCTION: This systematic review and meta-analysis aims to explore the influence of ferumoxytol versus placebo on iron deficiency anemia.
METHODS: We search for randomized controlled trials (RCTs) assessing the effect of ferumoxytol on iron deficiency anemia on PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases. This meta-analysis is performed using the random-effects model.
RESULTS: Four RCTs are included in the meta-analysis. Compared with the control group for iron deficiency anemia, intravenous ferumoxytol can significantly improve the proportion of patients with a ≥20 g/L hemoglobin (Hb) increase (RR = 18.43; 95% CI = 7.29-46.57; p < 0.00001), the proportion of patients with an Hb level ≥120 g/L (RR = 18.55; 95% CI = 8.66-39.72; p < 0.00001), transferrin saturation (mean difference = 11.08; 95% CI = 9.86-12.31; p < 0.00001) and FACIT-fatigue score (mean difference = 4.60; 95% CI = 3.21-6.00; p < 0.00001), but has no remarkable influence on adverse events (RR = 1.33; 95% CI = 0.84-2.10; p = 0.22), serious adverse events (RR = 1.22; 95% CI = 0.74-2.02; p = 0.44), and death (RR = 0.32; 95% CI = 0.05-1.95; p = 0.22).
CONCLUSIONS: Intravenous ferumoxytol can provide the important benefits for iron deficiency anemia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:142 |
|---|---|
| Enthalten in: |
Acta haematologica - 142(2019), 3 vom: 13., Seite 125-131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shao, Yanping [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.02.2020 Date Revised 11.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000498937 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300439180 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300439180 | ||
| 003 | DE-627 | ||
| 005 | 20231225102528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000498937 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM300439180 | ||
| 035 | |a (NLM)31434073 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shao, Yanping |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Efficacy of Ferumoxytol for Iron Deficiency Anemia |b A Meta-Analysis of Randomized Controlled Trials |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.02.2020 | ||
| 500 | |a Date Revised 11.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 S. Karger AG, Basel. | ||
| 520 | |a INTRODUCTION: This systematic review and meta-analysis aims to explore the influence of ferumoxytol versus placebo on iron deficiency anemia | ||
| 520 | |a METHODS: We search for randomized controlled trials (RCTs) assessing the effect of ferumoxytol on iron deficiency anemia on PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases. This meta-analysis is performed using the random-effects model | ||
| 520 | |a RESULTS: Four RCTs are included in the meta-analysis. Compared with the control group for iron deficiency anemia, intravenous ferumoxytol can significantly improve the proportion of patients with a ≥20 g/L hemoglobin (Hb) increase (RR = 18.43; 95% CI = 7.29-46.57; p < 0.00001), the proportion of patients with an Hb level ≥120 g/L (RR = 18.55; 95% CI = 8.66-39.72; p < 0.00001), transferrin saturation (mean difference = 11.08; 95% CI = 9.86-12.31; p < 0.00001) and FACIT-fatigue score (mean difference = 4.60; 95% CI = 3.21-6.00; p < 0.00001), but has no remarkable influence on adverse events (RR = 1.33; 95% CI = 0.84-2.10; p = 0.22), serious adverse events (RR = 1.22; 95% CI = 0.74-2.02; p = 0.44), and death (RR = 0.32; 95% CI = 0.05-1.95; p = 0.22) | ||
| 520 | |a CONCLUSIONS: Intravenous ferumoxytol can provide the important benefits for iron deficiency anemia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Ferumoxytol | |
| 650 | 4 | |a Hemoglobin level | |
| 650 | 4 | |a Iron deficiency anemia | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Randomized controlled trials | |
| 650 | 7 | |a Hemoglobins |2 NLM | |
| 650 | 7 | |a hemoglobin L |2 NLM | |
| 650 | 7 | |a 69071-62-1 |2 NLM | |
| 650 | 7 | |a Ferrosoferric Oxide |2 NLM | |
| 650 | 7 | |a XM0M87F357 |2 NLM | |
| 700 | 1 | |a Luo, Wenda |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Haiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Qunyi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta haematologica |d 1948 |g 142(2019), 3 vom: 13., Seite 125-131 |w (DE-627)NLM000152889 |x 1421-9662 |7 nnns |
| 773 | 1 | 8 | |g volume:142 |g year:2019 |g number:3 |g day:13 |g pages:125-131 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000498937 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 142 |j 2019 |e 3 |b 13 |h 125-131 | ||